Enanta Pharmaceuticals, Inc. (ENTA)
13.60
-0.20
(-1.45%)
USD |
NASDAQ |
Aug 28, 16:00
13.58
-0.02
(-0.11%)
After-Hours: 20:00
Enanta Pharmaceuticals Gross Profit Margin (Quarterly) : 91.75% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 91.75% |
| March 31, 2026 | 92.95% |
| December 31, 2025 | 93.39% |
| September 30, 2025 | 91.51% |
| June 30, 2025 | 93.39% |
| March 31, 2025 | 91.94% |
| December 31, 2024 | 94.76% |
| September 30, 2024 | 96.72% |
| June 30, 2024 | 96.69% |
| March 31, 2024 | 96.36% |
| December 31, 2023 | 96.43% |
| September 30, 2023 | 96.47% |
| June 30, 2023 | 96.55% |
| March 31, 2023 | 96.97% |
| December 31, 2022 | 97.83% |
| September 30, 2022 | 96.78% |
| June 30, 2022 | 96.32% |
| March 31, 2022 | 0.00% |
| December 31, 2021 | 0.00% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| Date | Value |
|---|---|
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 0.00% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 0.00% |
| September 30, 2017 | 0.00% |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
| March 31, 2016 | 0.00% |
| December 31, 2015 | 0.00% |
| September 30, 2015 | 0.00% |
| June 30, 2015 | 0.00% |
| March 31, 2015 | 0.00% |
| December 31, 2014 | 0.00% |
| September 30, 2014 | 0.00% |
| June 30, 2014 | 0.00% |
| March 31, 2014 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Perspective Therapeutics, Inc. | -1.31K% |
| AbbVie, Inc. | 74.71% |
| Coherus Oncology, Inc. | 64.33% |
| BridgeBio Pharma, Inc. | 93.68% |
| RenovoRx, Inc. | 84.27% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -64.75% |
| Return on Assets | -20.60% |
| Return on Invested Capital | -21.68% |
| Profit Margin (Quarterly) | -135.8% |
| Operating Margin (Quarterly) | -120.0% |
| Return on Net Operating Assets | -80.14% |